Ashland Inc. Common Stock (ASH)

Ashland (NYSE:ASH) reported higher sales across all four business units in its fiscal third quarter of 2026, supported by volume growth, pricing actions and demand in its Life Sciences and Personal Care operations. The company reaffirmed its full-year sales and adjusted EBITDA outlook, while lowerin

Ashland Inc (NYSE:ASH) beats earnings expectations for Q2, reports $1.02 EPS and $497.000M sales. Analysts maintain outperform ratings and raise price targets.

Ashland (ASH) Q2 2026 Earnings Call Transcript

Ashland (ASH) Q3 2025 Earnings Transcript

Ashland (ASH) Q4 2025 Earnings Transcript

Ashland (ASH) Q1 2026 Earnings Call Transcript

Markets gave up ground to start the new month.

GSK PLC is a Zacks Rank #5 (Strong Sell) after the company beat the Zacks Consensus Estimate when the last reported.